Capacity

Is the Bioreactor Arms Race Over?

David Alvaro, Ph.D.

Pharma's Almanac

Lipase Risk

An Integrated Analytical Approach to Lipase Risk Management in Biologics Development

Kyeyeon Hur, Ph.D.; Jimin Kim, Ph.D.; Minjeong Lee; Soojeong Oh; Woojung Jun

Samsung Biologics

Prevention

Preventive Therapeutics Beyond Vaccines

David Alvaro, Ph.D.

Pharma's Almanac

Masked Antibody

Expanding the Oncology Therapeutic Window Through Masked Antibody Technology

Sean McCarthy, Ph.D; David Alvaro, Ph.D.

CytomX Therapeutics

Self-Injection

The Quiet Revolution in How We Take Our Medicine

Ravi Kumar

OneSource Specialty Pharma

Critical Materials

Securing Critical Materials for Resilient Biopharmaceutical Manufacturing

Pharma's Almanac

Vaccines

The Next Generation of Vaccine Platforms

David Alvaro, Ph.D.

Pharma's Almanac

AI-Optimized CLD

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

Drug–Device

Designing Formulations Around Devices Rather Than Vice Versa

Pharma's Almanac

Protein Conformation

Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles

David Alvaro, Ph.D.

Pharma's Almanac

Cell-Free Synthesis

Cell-Free Biomanufacturing and the Future of Flexible Biologics Production

David Alvaro, Ph.D.

Pharma's Almanac

Digital Sampling

Enhancing Quality and Environmental Monitoring Efficiency Through Paperless Sampling

Jiwoon Kim; Neulbit Kim; Hyeonjung Park

Samsung Biologics

Protein Engineering

Exponential Advances in Protein Engineering

Cynthia A. Challener, Ph.D.

Pharma's Almanac

BsAbs

Why Bispecific Antibody Architecture Is a CMC Decision

David Alvaro, Ph.D.

Pharma's Almanac

NGIB

Rethinking Fermentation: Halophiles and the Next Generation of Industrial Biotechnology

David Alvaro, Ph.D.

Pharma's Almanac

ADC Engineering

Engineering Antibodies for Precision Payload Delivery

David Alvaro, Ph.D.

Pharma's Almanac

Carbon Footprint

Product Carbon Footprint: Enabling Product-Level Decarbonization in Biopharma

Jimin Han

Samsung Biologics

PAT

Real-Time Insight in Biologic Manufacturing: Why PAT Matters for Commercial Scale-Up

David Alvaro, Ph.D.

Pharma's Almanac

PAT

From Analytical Visibility to Real-Time Control in Biologics Purification

David Alvaro, Ph.D.

Pharma's Almanac